Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 52

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 52
---
. The compensation committee considered information presented by our management on our company-wide performance against goals and the individual contributions of the named executive officers toward achievement of the goals. Scoring for each category and total bonus funding is capped at 200% of target. We believe the final score assigned for each goal underscores both the rigor of the goals set and the discipline applied by the compensation committee in determining achievement. The 2024 bonus pool was funded at 78% of target for our chief executive officer and 90% of target for our other named executive officers, based on the following 2024 goals and achievement determinations: • Commercial . The commercial goals consisted of (i) a net sales target, which is a metric we have highlighted in our corporate goals for many years, and (ii) a hospital sales target, which is intended to provide a goal within the direct control of our employees. The compensation committee determined achievement of the net sales goal at 42% of target, and the hospital sales goal at 150% of target as our team exceeded the hospital sales goal. • Research and Development . The research and development goals consisted of an ampreloxetine enrollment goal, which was determined to be at 50% of target achievement. • Corporate . The corporate goals consisted of (i) an operating expense goal, which was determined to be achieved at 110% of target, (ii) the identification and development of one to two corporate or business development transactions, which was determined to be achieved at 75% of target, (iii) the finalization of decisions to optimize our corporate tax structure and implementation of such plan, which was determined to be achieved at 175% of target and (iv) an employee centered goal focused on attracting, retaining and developing diverse, engaged and passionate talent through comprehensive engagement and recognition initiatives, which was determined to be achieved at 100% of target. The compensation committee exercised its discretion to slightly increase the bonus percentage awarded to Mr. Winningham above actual achievement of the corporate goals as weighted for him from 78% to 80% achievement and decrease the bonus percentage awarded to our other named executive officers for 2024 performance below the actual achievement of our corporate goals in order to award certain non-executive employees increased bonus amounts without increasing the costs of the 2024 bonus program. The total cash bonuses awarded to our named executive officers are shown in the table below:

| Name             | ​ | ​ | Title                                              | ​ | ​ | Cash Bonus ($) |   |         |   | ​ |